All News
RheumNow Podcast - MTX vs. Etanercept in Psoriatic Arthritis (2.15.19)
Dr. Jack Cush discusses the news from the past week on RheumNow.com - including the SEAM trial, MRI guided T2T, biologics and infection, contraceptive use, ANA negative lupus, etc.
Read Article
Stopping Biologics Before Joint Surgery: Is Earlier Better?
d
RheumNow
Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.
Read Article
"In order to solve a problem, you need to sell it first.....remarket your problem with a story that resonates." - Seth Godin https://t.co/HHF9eMV7sk
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Orrin Troum shows data on ANA negative pts. Should this include those with cytoplasmic staining? #RWCS2019 https://t.co/EDV882CQ9E
Dr. John Cush RheumNow ( View Tweet)
Dr Orrin Troum shows that TB Tspot is more sensitive than QFT in school of TB. But no specificity data. #RWCS2019 https://t.co/KJ2i0EKim3
Dr. John Cush RheumNow ( View Tweet)
The RheumNow Weekly Podcast is up! Info on SEAM-PsA, SEAM trial, MRI T2T, biologics & infection, contraceptive use, ANA negative lupus. View here>> https://t.co/tv2ANE0LAp or listen on iTunes or SoundClound https://t.co/uXZEI1jmkJ
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens. Other arc options for localized scleroderma include tocilizumab and abatacept. #RWCS2019 https://t.co/AIfARTZ3CD
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens shows that CARRA pediatric rheums treat localized scleroderma with steroids and MTX #RWCS2019 https://t.co/h9s5Owz8J3
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens compare localized and diffuse pediatric scleroderma #RWCS2019 https://t.co/KJLGHlvqiE
Dr. John Cush RheumNow ( View Tweet)
FREEDOM trial 3,591 postmenop. women Rx w/ denosumab vs PBO x3 years - No difference in dental procedures (~45%), adjudicated osteonecrosis of jaw (13 cases) - risk was 0.68% vs. 0.05% w/ and withour invasive oral procedures. https://t.co/dxWuzEjUnk
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman shows that filgotinib (Jak inhibitor) maybe effect in ankylosing spondylitis. #RWCS2019 https://t.co/0km5vMHFpQ
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman shows data on the lack of effect with ustrkinumab in biological naive ankylosing spondylitis. #RWCS2019 https://t.co/Wqx7Us1Qrl
Dr. John Cush RheumNow ( View Tweet)
Dr Mark Genovese on Filgotinib (jak 1 inhibitor in development) showing no diff in responses despite falling 1, 2, 3 biologics #RWCS2019 https://t.co/dk7orkumEd
Dr. John Cush RheumNow ( View Tweet)
Dr Aryeh Fischer say bronchiolitis is the most devastating of lung dz in our pts. Small airway obliterative dz. w obstructive PFTs but poorly responsive. Consider it pts w refractory severe asthma #RWCS2019 https://t.co/VNGTNbXLEK
Dr. John Cush RheumNow ( View Tweet)
Dr Aryeh Fischer on MTX lung dz - it is rare. #RWCS2019 https://t.co/pIQvv0jEFW
Dr. John Cush RheumNow ( View Tweet)
Dr Aryeh Fischer on risk factors for ILD. #RWCS2019 https://t.co/a86BBgxEMm
Dr. John Cush RheumNow ( View Tweet)
Dr Aryeh Fischer on ILD increasing #RWCS2019 https://t.co/euvky7H3Bs
Dr. John Cush RheumNow ( View Tweet)
Good morning from #RWCS2019! Year in Review #1: HCQ doesn't work for hand OA, so stop using it! Jack Cush @RheumNow has talked about this multiple times on his podcast. I'd say the same for Sjogrens (see my podcast on JOQUER trial), but that's more controversial. https://t.co/fmb2bfVhg0
Mike Putman EBRheum ( View Tweet)
Analysis of a large Pediatric hospital database and 5679 SLE admissions shows that 12.4% had Pericardial Effusion (PCE) at entry. PCE was assoc w/ 2.5 higherrisk of In-hospital mortality(p 0.027) and 1.5 time more 30Day readmissions (p 0.001). https://t.co/XS6FEGfdH5
Links:
Dr. John Cush RheumNow ( View Tweet)
927 Lupus registry study shows that use of combined hormonal contraceptives was low (8%) and nearly half (55%) took place in the setting of possible contraindication such as aPL (52%), HTN (34%), migraine with aura (22%). More study and info is needed https://t.co/yTCKbRTp2m
Links:
Dr. John Cush RheumNow ( View Tweet)